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doi:10.1016/j.jfma.2011.11.026Background/Purpose: Automation has long been awaited in parenteral drug dispensing. Phar-
macists can benefit much in theory from a good automated device to handle the hazardous
drugs used in chemotherapy. This paper describes the performance of the first
chemotherapy-dispensing robot in the oncology pharmacy of a 2500-bed medical center. The
objective of this paper is two-fold: (1) to assess the robot’s performance in terms of its success
rate and to summarize the causes of failure, and (2) to find out if the robot can decrease the
full-time equivalents (FTEs) of the oncology pharmacy.
Methods: We used the computer-generated log from the first week of May 2010 to that of July
2010, supplemented with the pharmacists’ notes on the causes of failure, to determine the
success rate and to analyze the incidences of failure. We also assessed the FTEs before and
after implementing the robot.
Results: Data showed that the success rate rose slowly from 76.8% to 95.3% over the 2-month
recording period. The major mechanical problems encountered were air, clamping, and waste
bin problems. Manual errors, such as loading wrong drugs or syringes, also caused failures. In
terms of manpower saving, CytoCare failed to decrease the number of FTE pharmacists/tech-
nicians in our oncology pharmacy practice.
Conclusion: We conclude that even though CytoCare could ease the risk of chemotherapy
exposure and increase the precision of dosing, it was not able to improve the FTE pharma-
cists/technicians in our hospital.
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software (CytoPlan). A pharmacist needs to key in a drugThe fact that healthcare workers, while preparing or
administering chemotherapy, are exposed to the toxic
effects of these hazardous drugs has been well doc-
umented.1e10 Manual dispensing of chemotherapy has been
the norm in a hospital for a long time, although automation
technology is on the rise in other dispensing work.11e16 This
is mainly because the dispensing of parenteral chemo-
therapy needs to consider stringent environmental control
standards and personnel safety. Automation technologies
have failed to produce a system for this complicated task in
the past until recently. CytoCare, manufactured by Health
Robotics GmbH with its headquarters in Bolzano, Italy, is
the first automatic processor for the preparation of
chemotherapy injections in a sterile environment in the
world.17
Automation in chemotherapy dispensing has the ability
to lower the exposure of pharmacists to hazardous drugs
mainly because it replaces human manipulation of these
drugs. However, in case of mechanical problems, ease of
handling these problems needs to be assured as well.
Besides the safety benefit, one would also hope that
automation can elevate the accuracy and efficiency of the
dispensing job. Many automated devices, such as carousel-
dispensing technology, have been proved to improve the
overall efficiency of medication distribution in inpatient
service.18 The new chemotherapy-dispensing robot will also
need to be validated to see if it can do the same. Many
technicians or pharmacists are afraid of their roles being
replaced by automation.19,20 However, the possibility of
decreasing full-time equivalents (FTEs)21,22 can actually
leave the pharmacists more time to help with clinical
services.
Our hospital is one of the major medical centers in
Taiwan. This tertiary medical center is located in the hub of
the capital city and has over 2500 beds in total. Cancer
patients are one of the main patient populations. The
oncology pharmacy is equipped with facilities that meet
USP 797 standards23 on the pharmaceutical compounding of
sterile preparations and is responsible for chemotherapy
for outpatients in the oncology clinic, as well as for inpa-
tients. The oncology pharmacy, on average, dispenses more
than 300 doses of chemotherapy per day. The pharmacy
staff includes 11 FTE pharmacists and three FTE pharmacy
technicians for the dispensing-related work. The pressure
of filling so many prescriptions per day and the current
knowledge of safety requirements24,25 in handling
hazardous drugs prompted us to look for automated facili-
ties. The search for an automated robot began in 2006.
After installation and a testing period, we began its routine
use in May 2010.
CytoCare consists of many different parts, its primary
feature being a multiaxis robotic arm that does the main
dispensing job. The machine is also equipped with five high-
efficiency particulate air filters to provide an ISO class-5
environment for the dispensing process. It has a shaker,
a camera for confirming the drug used, and an inbuilt scale
to double-check the amount of the drug. A carousel for
loading drugs, diluents, or syringes is located in the loading
area. As CytoCare cannot handle glass ampoules, only drugsin vials are used. The whole robot is operated by computer
database in the preparatory stage. When the robot is used
routinely, the pharmacist can key in necessary data from
the prescription and, at the same time, arrange the
sequence of all doses to be made. If an interface is devel-
oped to connect the in-house Computerized Physician
Order Entry (CPOE) system with CytoPlan, the key-in
process can be bypassed.
The design of the robot has the benefit of avoiding direct
human contact with the hazardous drugs, thus improving
safety. Another feature of the robot is that it can use drug
density and the dose required to get the calculated volume.
It also measures the actual weight of the vial before and
after the liquid has been drawn up in a syringe to confirm
the exact volume drawn. If the volume of the drawn liquid
differs by more than 5% from the calculated volume, the
robot will reject the product and label it as a failure. From
the manufacturer’s data, the accuracy of the chemo-
therapy dispensed by the robot shows an error rate of less
than 2.5%. For a syringe to draw 20 mL liquid, the error rate
is less than 0.5%. Manual work can never reach this preci-
sion, because of not only the limitations in human hands
and eyes, but also the lack of precision in the graduations
on the syringe. Thus, the robot should provide more accu-
rate dosages to patients.
The purpose of this study is to describe the performance
of this novel robot in dispensing chemotherapy in terms of
its success rate and the major causes of its failures. We also
want to compare the efficiency of automation to that of
manual work by comparing the FTEs. As far as we know, this
is the first report on this specific type of automated robotics
used for the dispensing of chemotherapy.
Methods
We collected the related data of CytoCare for 2 months
from May 4, 2010 to July 9, 2010. Out of the 10 weeks,
CytoCare operated routinely only on 47 days (94% of the 50
pharmacy work days). This was because the engineer
needed to test the robot on certain days and routine use of
the robot was not possible. The robot had its own
computer-generated daily and monthly log of the drugs that
it dispensed, with the number, but not the cause, of fail-
ures being recorded. After CytoCare finished a daily
assignment, the pharmacists would edit the log to explain
the reasons for its failure. The definition of failure for the
robot was a self-detected difference of greater than 5%
between the drawn dose and the calculated dose (air
failure), or when the robot aborted the operation due to
other mechanical or manual problems (non-air failure). Air
failure was caused when air, in addition to drug, was drawn
into the syringe, resulting in a difference of greater than 5%
from the calculated volume. If the robot failed to produce
an acceptable dose, it would eject the syringe to its loading
area and warn the pharmacist by showing the status of
“failure” on the operation screen. All the other doses were
counted as successful.
The daily number of failures and the weekly success rate
were documented. Causes of failure were further analyzed.
In the analysis, we used cumulated doses because these
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cumulative failed doses could be compared to total
prepared doses. This was done in the hope of detecting the
most frequent cause of failure during this period of time.
We also tried to perform linear regression analyses on
the failed doses. This would mainly show if the failure
occurs at a steady rate. If the linear regression line is a best
fit for all dots, it indicates that the failure is occurring at
the same rate. If, however, the dots are best fit with two
different lines, it would imply that other factors have come
in to change the failure rate.
The influence on the saving of manpower was assessed
by summarizing what we viewed from the logs. Prior to the
use of the robot, we had 14 FTEs of pharmacists/techni-
cians. We assumed that a pharmacist/technician could
dispense 20 doses of chemotherapy per hour (data on file).
This was then compared with the average number of doses
made by CytoCare per hour to see how many person-hours
it saved. Every 8 person-hours were equivalent to one FTE.
This was the gross impact of CytoCare on manpower
saving.
Results
Chemotherapy dispensed by CytoCare
WeusedCytoCare in our pharmacy for twopurposes. Thefirst
was a preparatory purpose. 5-Fluouracil (5-FU) was one of
the most frequently prescribed chemotherapeutic agents at
our hospital. Because the daily number of doses was large,
we used CytoCare as the main tool for pre-filling 5-FU
syringes. The pharmacists/technicians then adjusted the
dosages and completed the dilution process. Secondly, we
used CytoCare to help with daily online prescriptions. So far,
only a limitednumberof chemotherapeutic agentswereused
in CytoCare, namely, 5-FU 1 g/vial, carboplatin 150 mg/vial,
cisplatin 50 mg/vial, cyclophosphamide 500 mg/vial,
cytabine 500 mg/vial, epirubicin 50 mg/vial, ifosfamide 2 g/Figure 1 Daily total doses and failed doses produced by the robot
solid and the dotted lines represent the number of total doses andvial, methotrexate 1 g/vial, oxaliplatin 50 mg/vial, and leu-
covorin 50 mg/vial (not a chemotherapeutic agent itself, but
is commonly used in our pharmacy). For most of the total
doses made in this study 5-FU was used (551 doses, 53.6%),
followed by cyclophosphamide (22.3%), cytarabine (6.8%),
carboplatin (4.7%), methotrexate (4.6%), and ifosfamide
(4.2%); each of the rest of the drugs made up less than 2% of
the total. The reason for the limitation of drugs usedwas that
some chemotherapeutic agents available in Taiwan are
either glass ampoules or available in small volumes; it would
take much longer to draw large doses of these than of agents
that are available in larger-volume vials. We, thus, chose
more widely used chemotherapeutic agents to be dispensed
by the robot. Vials ofwater for injectionwerenot available in
Taiwan; hence, we were unable to use CytoCare to recon-
stitute powdered drugs.Failure and success rate of CytoCare
Fig. 1 showed the daily total number of doses dispensed by
the robot on Day 1 through Day 47 of CytoCare operation.
From the data, we could see that the number of doses that
CytoCare produced daily was between 1 and 47. The total
number of doses made by CytoCare during this period of
time was 1028. The number of doses made per day gradu-
ally increased as the days went by, largely due to the
pharmacists’ increasing familiarity with the machine over
time. The pharmacists gradually tried to make online orders
in the morning, while in the less busy hours they used
CytoCare for preparatory doses (pre-filled 5-FU). Another
reason for this steadily rising trend was that the onsite
engineer solved many problems and the process became
much smoother. In the sixth week (Days 24e28), the engi-
neers were changing the syringe system from a BD to
a Terumo mode, which resulted in lowering of the daily
totals. Regular dispensing work was delayed by much
testing.in the 47 days of CytoCare operation during the 10 weeks. The
failed doses, respectively.
Figure 2 Weekly success rate of CytoCare. The success rate was evaluated by dividing the number of successful doses, as defined
in the text by total doses prepared by CytoCare in each respective week. The success rate increased from 76.8% in the first week to
90% or above after the sixth week.
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week to 95.3% in the 10th week (Fig. 2), indicating
a smoother process in the later stages.Air failures and non-air failures
Out of the total of 1028 doses made by CytoCare during this
period of time, 123 doses (12.0%) failed. The causes of
failure were categorized into two groups: air and non-air
failures (Fig. 3A). The non-air failures included loading,
clamping, waste bin, and others (Fig. 3B). The loading
failure was caused by manual errors, while all other were
mechanical failures.
From the cumulative failing doses, one could see that
the most frequent failure was an air failure (98 of 1028 total
doses, 9.53%), which was caused by drawing of air in
addition to drug into the syringe, resulting in a difference
of greater than 5% from the calculated volume. This was
followed by non-air failures, namely, loading failure,
clamping failure, waste bin failure, and others. If we
examine the air failures in more detail, 5-FU was associated
with the highest number of failing doses due to an air
problem (63 doses) because it was the most frequently
dispensed drug. The drugs with the highest percentage of
failure due to this problem also included epirubicin (eight
failures out of 16 doses, 50%), carboplatin (six failures out
of 48 doses for carboplatin, 12.5%), and cisplatin (two
failures out of 16 doses for cisplatin, 12.5%).
It can be seen from Fig. 3A that the data were best fit by
two least-squares lines for both the air and non-air failures.
Line “Air a” describes the initial operation period, whereas
line “Air b” describes the second period. The slope of line
“Air b” is about half of the slope of line “Air a”, indicating
that the failure rate was approximately halved (from 11.5%
to 6.0%) in the second period. This transition in failure rate
occurred around a cumulative dose of 500. This was in the
sixth week, when we switched our syringe system. Since the
installment of the new syringe grips, the air problem
dramatically decreased. The failure rate of non-airproblems was also reduced (2.6% to 1.7%) around the
cumulative dose of 450, which was in the fifth week (Days
20e23). At this time, the engineers were fine-tuning the
robot to help maintain the system. The stability of the
robot seemed to improve (fewer clamping and waste bin
failures). This might have contributed to the lower failure
rate in the second period (“Non-air b” line).
The second most frequent failure, loading failure (seven
in 1028 doses, 0.68%), was a manual problem, as seen in
Fig. 3B. While loading the syringe, one had to make sure
that the plunger was completely pushed in; otherwise, the
robot could not put the syringe into the drawing position
(too long a syringe). In many cases, the failure occurred if
the plunger was not properly pushed in.
The next cause of failure was a mechanical one, namely,
the clamping failure. It had the same frequency as the
loading failure (seven in 1028 doses, 0.68%). The fourth
most frequent failure was also a mechanical problem, the
waste bin failure (six in 1028 doses, 0.58%). Lastly, the
causes behind “others” included two power failures and
three failures that occurred during testing (five of 1028
failed doses, 0.49%).
Manual problems, as reflected in the loading failures,
lessened as pharmacists became more familiar with the
process. Mechanical problems, such as the waste bin and
clamping failures, were not frequent and normally could be
fixed by the local engineer instantly, so they posed no
serious trouble. The air failure remained the unresolved
issue despite its rate being decreased by 50% over time. As
we have explained earlier, the change of the syringe system
was one of the factors that contributed to lowering of the
failure rate. The complete solution to this failure remained
to be elucidated, although selecting proper-sized vials to
be dispensed by CytoCare might lower future air problems.FTEs saved
We compared the number of doses that CytoCare made in
a day with daily manual production. In this period of
Figure 3 (A) Cumulative number of air and non-air failures graphed as a function of cumulative total doses. Linear regression
analysis determined the failure rates as shown. (B) Main contributors to the non-air failures in Fig. 3A. Problems are listed in order
of frequency. A detailed description may be found in the “Causes of failure” section.
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CytoCare was 47. This was approximately equivalent to
a gross saving of 2 person-hours a day, based on the data
that a trained pharmacist can dispense 20 doses per hour.
However, we had to have a pharmacist or a technician to
switch on and off CytoCare repeatedly during the whole
day. This included keying-in commands for the robot,
preparing and loading the robot with appropriate drugs and
syringes, as well as taking out products, handlingproblems, and so on. The work was approximately 6
person-hours per day (75% of the daily work). So the time
and personnel saved were not able to compensate for the
time spent on maintaining the routine operation of the
machine. In addition, an onsite engineer was required to
stand by to monitor and to help sort out possible failure
issues, adding to the time and personnel involved. Cyto-
Care was not able to lower FTEs for our oncology
pharmacy.
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Causes of failures
Air failure
According to the results, epirubicin, carboplatin, and
cisplatin had the highest air-failure rates. The main reason
for the failure with these drugs was that the dosages
prescribed were relatively large and they used up almost all
the contents in the vial. For example, for 100 mg of epi-
rubicin (available as 50 mg/25 mL vials), CytoCare would
need to draw up two 25-mL vials. Because of the lack of
dexterity in the robotic arm, it tended to draw up too much
air when it came to the last bit of liquid.
Other reasons for air failures included our use of a ven-
ted needle for the syringe to avoid spraying contaminating
aerosols in the machine. When the vented needle was
inserted into the drug vial, it could easily introduce air into
the vial, causing air to enter into the syringe as well. Even
though the robot always tilted the vial at an angle of around
15 to try to keep the tip of the needle below the surface of
the liquid, it was unable to adjust the position of the vial to
always do this. It was thus possible to draw air in addition to
drug into the syringe, causing failure (>5% error). Another
possible cause of the air failure was the robot’s inability to
differentiate between an intact vial and a partly empty
vial. Approaching a partly empty vial, it still drew the
syringe’s plunger to its full length to get enough drug,
drawing air into the syringe. To summarize, if we could find
larger vials with volumes that could allow partial drawings
to fit all dosage ranges for the drugs, the air problem could
be lessened.
Non-air failure
Loading failure
Loading failure was a manual problem. It could only be
prevented by teaching the pharmacists to ensure that all
the plungers of the syringes are tightly pushed in and
placed into the robot in the proper direction so that the
needle can effectively draw up the liquid.
Clamping failure
During the weighing procedure, the robotic arm would
occasionally fail to put the vial at the correct position, and
later be unable to clamp onto the vial and pick it up. This
failure required the engineer to adjust the position of the
clamp by trial and error. It would still occur occasionally,
mainly because of variations in the packaging of vials. The
differing shapes and sizes of vials could cause some diffi-
culties. A certain set of parameters regarding the shape
and size of vials was saved in the database; if the shape of
a vial was different from the average, for example in the
curvature of the neck area, the system would show
a failure sign. Furthermore, when the clamp was about to
pick up the upper portion of the vial, it would sometimes
hit the top and thus be unable to secure the vial in an
upright position. This unpredictable problem required
a manual adjustment to be fixed. Another problem
occurred when the robot had already completed drawingthe chemotherapy and wanted to put the needle cap back
onto the syringe. If for some reasons the axis of the robot
had been moved, as might happen in the cleaning proce-
dure every afternoon, it would not aim at the correct
position and thus be unable to pick up the needle cap; this
would result in failure.
Waste bin failure
When CytoCare’s robotic arm threw away the used vials or
other waste into the waste bin, the lid of the bin had to
move away and then reposition itself back to home posi-
tion. Sometimes, it was not able to move back to home
position and would cause an alarm to go off, reflecting
failure. After our local engineer adjusted some parameters
to control the moving of the lid, this problem was mainly
solved, except some occasional instances when it would
still come up.
Other failures
The two power failures were unavoidable and unpredict-
able. Although CytoCare was hooked to a UPS system, in
this type of instant electrical interruption, the task that
was underway would be aborted. One could still take out
the syringe manually and finish the task either by re-
entering it into the robotic system or by hand. As to the
remaining failures, the manual record only noted that these
were the doses tested by the engineer and gave no further
explanation.
Lack of influence of the robot in daily practice
Speed
The manufacturer of CytoCare stated its benefits of safe-
guarding the staff from chemotherapy contamination and
ensuring precise dosing (>95% precision). However, the use
of CytoCare did not have a great influence on our practice
because of its several limiting factors. One major limitation
of CytoCare was its lack of speed in making the doses. Since
our pharmacy was located in a medical center, the number
of doses of chemotherapy to be prepared each day was
more than 300; in contrast, the maximum number of doses
that CytoCare can prepare, in our experience, was
approximately 50. Manually drawing the drug into a syringe
could be done within 3e5 minutes. The average time
required for CytoCare to do the same job was about 10e20
minutes, depending on the dosage and the availability of
larger drug vials. This was the main reason why CytoCare
could only make a limited number of doses of chemo-
therapy. This facet of CytoCare’s performance limited its
use mainly to inpatients, because outpatients normally
could not tolerate waiting for more than 30e60 minutes for
their chemotherapy to arrive.
Because of this limitation, pharmacists had to work on
the rest of the prescription orders, plus one person always
needed to keep an eye on the robot for the loading
requirements and other possible alarms.
Another limiting factor in terms of its performance was
the delicacy of the robotic arm. Any minor alteration of
the vial shape, labeling of the vial, or change in the axis of
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listed in Fig. 3A and 3B resulted from a minor maladjust-
ment of the robotic arm. The engineers are still working on
the air failure and hopefully would be able to decrease it,
improving the performance of CytoCare. The performance
will also improve once larger chemotherapy vials are
available. A similar situation exists with the less frequent
clamping and waste bin failures. An onsite engineer is
needed to stand by to readjust the positioning of the
robotic arm and the waste bin to curtail these problems.FTEs
The guarantee period of the robot was limited (2 years in
our hospital). In special cases, engineers from Italy, or an
engineer who was in the Asia district, would fly to the site
to fix the robot. This service was provided for free within
the guarantee period. If an onsite engineer is needed for
adjusting the many minor problems that can block the
normal functioning of CytoCare, we would need to hire this
personnel at an extra cost after the guarantee period
expires. A contingency plan should be developed for our
own personnel to be trained further to understand more
day-to-day operation details in order to maintain a smooth
run. The local engineer recently provided us with
a problem-solving brochure, so pharmacists could try to
solve some of the issues themselves prior to asking the
engineer to help.
In terms of cost saving, so far the net influence on FTEs
was a negative one. The requirement for personal protec-
tive equipment (including hair covers, shoe covers, water-
proof gowns, gloves, and masks) was not reduced, and the
use of other consumables, such as syringes or vented nee-
dles, was the same as, if not more than, in manual work.
Person-hours saved could not offset the attention needed
by extra manpower.Conclusion
Reports have shown that informatics and automation are
important tools for the reduction of work, error, and cost in
a hospital pharmacy.11e17,26 CytoCare is the first automatic
dispenser for parenteral chemotherapy.17 From our
preliminary experience, this robot could so far save
approximately 2 person-hours per day, although it was not
able to make up for the person-hours spent on running the
robot, i.e., it had no real benefit in cutting FTEs. If the
inherited problems can be further solveddfor example, if
the air issue can be taken care of by having larger vials
available and if the engineer can develop ways to increase
the stability of the machinedthe performance will
improve. If we can also develop the interface between our
CPOE system and the software (CytoPlan), the speed and
scope of the operation of CytoCare in our hospital will be
improved. Despite these facts, we are still much obliged to
the hospital for purchasing this first robot for chemotherapy
in the pharmacy department, and we will try our best to
accommodate the robot in our working schedule and
maximize its usage.Acknowledgments
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